Spero Therapeutics, Inc. (SPRO) Financial Ratios
11 years of historical data (2015–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: 0.33
30Y Low0.3·High0.3
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
2.21
+3% vs avg
5yr avg: 2.14
30Y Low0.4·High5.6
ROE
↑
16.3%
↓+144% vs avg
5yr avg: -37.3%
30Y Low-101%·High25%
Debt/EBITDA
N/A
—
5yr avg: 0.25
30Y Low0.3·High0.3
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
SPRO Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Spero Therapeutics, Inc. trades at 14.7x earnings, 55% above its 5-year average of 9.5x, sitting at the 50th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a discount of 33%.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $128M | $138M | $56M | $78M | $65M | $495M | $434M | $175M | $98M | $30M | — |
| Enterprise Value | $91M | $100M | $7M | $7M | $-37437820 | $389M | $357M | $151M | $64M | $-56892336 | — |
| P/E Ratio → | 14.73 | 15.53 | — | 3.42 | — | — | — | — | — | — | — |
| P/S Ratio | 2.15 | 2.31 | 1.16 | 0.75 | 1.34 | 161.12 | 46.52 | 9.63 | 24.81 | 15.36 | — |
| P/B Ratio | 2.21 | 2.33 | 1.21 | 0.73 | 0.86 | 5.60 | 3.29 | 2.34 | 0.85 | 0.36 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
SPRO EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.68 | 0.15 | 0.07 | -0.77 | 126.84 | 38.23 | 8.29 | 16.22 | -28.75 | — |
| EV / EBITDA | — | — | — | 0.33 | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | 0.27 | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
SPRO Profitability
Margins and return-on-capital ratios measuring operating efficiency
Spero Therapeutics, Inc. earns an operating margin of -0.0%. Operating margins have compressed from 20.7% to -0.0% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 16.3% indicates solid capital efficiency.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | -101.7% | 50.4% | 100.0% | 100.0% | -618.1% | -262.5% | -754.4% | -1560.9% | -7760.6% |
| Operating Margin | -0.0% | -0.0% | -152.9% | 20.7% | -86.9% | -2865.5% | -847.9% | -348.4% | -1079.3% | -2108.6% | -9916.7% |
| Net Profit Margin | 14.4% | 14.4% | -142.9% | 22.0% | -95.5% | -2923.6% | -839.0% | -335.7% | -1050.5% | -2329.3% | -7609.3% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 16.3% | 16.3% | -89.6% | 24.9% | -56.5% | -81.5% | -75.8% | -63.9% | -41.3% | -100.6% | -835.2% |
| ROA | 9.6% | 9.6% | -46.8% | 14.8% | -31.4% | -55.3% | -60.3% | -51.8% | -37.5% | -86.0% | -243.4% |
| ROIC | -0.2% | -0.2% | -327.2% | 336.4% | — | -349.9% | -113.0% | -71.6% | -80.1% | — | — |
| ROCE | -0.0% | -0.0% | -71.0% | 17.3% | -33.0% | -60.4% | -72.4% | -64.5% | -42.4% | -90.5% | -873.2% |
SPRO Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $40M exceeds total debt of $3M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.05 | 0.05 | 0.09 | 0.05 | 0.09 | 0.08 | 0.06 | 0.07 | — | — | — |
| Debt / EBITDA | — | — | — | 0.25 | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.63 | -1.05 | -0.66 | -1.35 | -1.19 | -0.59 | -0.32 | -0.29 | -1.02 | -1.62 |
| Net Debt / EBITDA | — | — | — | -3.24 | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -16.82 | -45.27 | — | — | -141.27 | -137.72 | — |
Net cash position: cash ($40M) exceeds total debt ($3M)
SPRO Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Spero Therapeutics, Inc.'s current ratio of 7.59x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 3.53x to 7.59x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.59 | 7.59 | 2.19 | 3.53 | 5.04 | 8.46 | 9.70 | 3.58 | 9.37 | 10.70 | 1.72 |
| Quick Ratio | 7.59 | 7.59 | 2.19 | 3.53 | 5.25 | 8.46 | 9.70 | 3.58 | 10.08 | 11.29 | 1.72 |
| Cash Ratio | 4.54 | 4.54 | 1.08 | 2.05 | 5.04 | 7.84 | 8.85 | 3.08 | 9.37 | 10.70 | 1.49 |
| Asset Turnover | — | 0.87 | 0.43 | 0.57 | 0.39 | 0.02 | 0.06 | 0.17 | 0.03 | 0.02 | 0.02 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 155.42 | 399.23 | 178.30 | 8.14 | 314.00 | — | 206.08 | 119.46 | 542.80 | 331.22 |
SPRO Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Spero Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 6.8% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 6.8% | 6.4% | — | 29.3% | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $59M | $54M | $53M | $38M | $31M | $22M | $18M | $16M | $3M | $7M |
Peer Comparison
Compare SPRO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 SPROYou | $128M | 14.7 | — | — | 100.0% | -0.0% | 16.3% | -0.2% | — |
 VNDA | $355M | -1.6 | — | — | 94.0% | -70.0% | -50.9% | -32.2% | — |
 PRAX | $9B | -22.5 | — | — | — | — | -45.8% | -65.0% | — |
 NAOV | $512711 | -0.1 | — | — | 6.0% | -896.6% | -106.6% | -116.9% | — |
 AGEN | $127M | -894.1 | — | — | 29.6% | -18.0% | — | — | — |
 TBPH | $854M | 8.0 | — | 3.6 | 94.9% | -12.3% | 44.8% | -5.1% | — |
 IDYA | $3B | -26.7 | — | — | 97.9% | -72.8% | -10.9% | -12.4% | — |
 NKTR | $1B | -6.8 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 ACAD | $4B | 9.6 | 26.3 | 36.0 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 PFE | $143B | 18.4 | 10.3 | 15.7 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 MRK | $285B | 15.9 | 11.0 | 23.1 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 11 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
SPRO — Frequently Asked Questions
Quick answers to the most common questions about buying SPRO stock.
What is Spero Therapeutics, Inc.'s P/E ratio?
Spero Therapeutics, Inc.'s current P/E ratio is 14.7x. The historical average is 9.5x. This places it at the 50th percentile of its historical range.
What is Spero Therapeutics, Inc.'s ROE?
Spero Therapeutics, Inc.'s return on equity (ROE) is 16.3%. The historical average is -52.0%.
Is SPRO stock overvalued?
Based on historical data, Spero Therapeutics, Inc. is trading at a P/E of 14.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Spero Therapeutics, Inc.'s profit margins?
Spero Therapeutics, Inc. has 100.0% gross margin and -0.0% operating margin.